Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for ...
View upcoming earnings forecasts and in-depth analysis of company forecasts.
Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Cipher Pharmaceuticals (CPHRF – Research Report) today and set a price ...
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative ...
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, reported its financial and ...
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular ...
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, reported its financial ...
The 80's and 90's spawned a host of selling models and most of us in the pharma business have been trained to use one or multiple different selling models. However, how many pharma executives ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback